

Title	Number of respondents	Frequency of response	Number of responses	Hours per response	Total burden hours
Biennial Entity Verification Document .....	5,750	1	5,750	.25	1,438
Entity File Update .....	1,150	1	1,150	.25	288

Estimated Total Annual Burden: 167,489 hours

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Allison Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: December 14, 1995.  
 J. Henry Montes,  
*Associate Administrator for Policy Coordination*  
 [FR Doc. 95-30885 Filed 12-19-95; 8:45 am]  
 BILLING CODE 4160-15-U

**National Institutes of Health**

**Opportunity For Licensing: Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.  
**ACTION:** Notice.

**SUMMARY:** The National Institutes of Health (NIH) seeks licensees to commercialize a method to manipulate non-templated nucleotide addition to ensure that all amplified DNA products of polymerase chain reaction (PCR) are either specifically modified or unmodified.

This technology was developed by Dr. Jeffrey R. Smith and Dr. John Carpten of the National Center for Human Genome Research and Dr. Michael Brownstein of the National Institute of Mental Health.

The invention embodied in U.S. Provisional Patent Application 60/005, 761 filed October 20, 1995, entitled "Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition," is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 or pursuant to 42 U.S.C. 241 to achieve expeditious commercialization of results of federally-funded research and development.

**ADDRESSES:** Requests for a summary of the technology or other questions and comments concerning the biomedical aspects of this technology should be directed to: Dr. Ronald King, National

Center for Human Genome Research, 9000 Rockville Pike, Building 31, Room 3B13, Bethesda, MD 20892; Telephone: 301/402-2537; Fax 301/402-9722.

Requests for a copy of the patent application, license application form, or other questions and comments concerning the licensing of this technology should be directed to: Carol Lavrich, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone 301/496-7735 ext 287; Fax 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

**SUPPLEMENTARY INFORMATION:**

Thermostable DNA polymerases are employed in PCR to amplify DNA for sizing in medical diagnostics, forensics, and genotyping, as well as for molecular cloning. Several of these enzymes, including the widely used Taq DNA polymerase, can catalyze non-templated addition of a nucleotide (predominantly adenosine) to the 3' end of amplification products. As a result, an amplified DNA fragment may be incorrectly sized by one base pair in length and introduce error into a genotyping study. Artifactual variations in marker size may adversely impact interpretations of family relationships, medical diagnosis, and forensics. Moreover, full automation of genotyping has been hampered by the necessity of manually editing collected data to correct for allele misidentification due to the unpredictability of non-templated nucleotide addition. In addition, TA cloning methods that rely upon the modification will often fail when the amplified DNA is not modified.

In response to this problem, Drs. Smith, Carpten, and Brownstein have characterized short DNA sequences ("tails") that may be added to the unlabeled primer of a PCR primer pair to confer modification by a thermostable DNA polymerase, or to protect from the modification. This allows uniformity in allele sizing that is essential for automated genotyping. Furthermore, this prevents introduction of error and enables high TA cloning efficiency.

The NIH seeks licensee(s), who in accordance with requirements and regulations governing the licensing of government-owned inventions (37 CFR part 404), have the most meritorious

plan for the development of this method to meet the needs of the public and with the best terms for the NIH. The criteria that NIH will use to evaluate exclusive or non-exclusive license applications will include those set forth by 37 CFR 404.7(a)(1)(ii)-(iv).

Dated: December 8, 1995.  
 Barbara M. McGarey,  
*Deputy Director, Office of Technology Transfer.*  
 [FR Doc. 95-30935 Filed 12-19-95; 8:45 am]  
 BILLING CODE 4140-01-M

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.  
**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

**ADDRESSES:** Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting Robert Benson at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext 267; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

**Immunogenic Chimeras Comprising Nucleic Acid Sequences Encoding Endoplasmic Reticulum Signal Sequence Peptides and at Least One Other Peptide, and Their Uses in Vaccines and Disease Treatments**

Nicholas P. Restifo, Steven A. Rosenberg, Jack R. Bennink, Igor Bacik, and Jonathan W. Yewdell (NCI)  
 Serial Number 08/032,902 filed March 17, 1993

This invention concerns the use of chimeric peptides as vaccines for the cellular immune system. One portion of the chimeric peptide, the ER signal peptide, serves to transport the chimeric

peptide from the cytoplasm to the ER. Once in the ER, the other portion of the chimeric peptide associates with class I MHC molecules and together they form a complex which is presented on the surface of the cell. The complex activates cytotoxic lymphocytes which react with the complex, leading to expansion of CTLs which kill cells presenting the particular complex. The MHC complexing portion of the chimeric peptide is taken from cancer antigens or viral antigens. Thus the invention is a broad general method of vaccination that activates the cellular immune system. DNA constructs and expression vectors encoding the chimeric peptides are also claimed. The method has been shown to work as a treatment for cancer in mice. It has been PCT filed, PCT/US94/02897.

Dated: December 8, 1995.

Barbara M. McGarey,

*Deputy Director, Office of Technology Transfer.*

[FR Doc. 95-30936 Filed 12-19-95; 8:45 am]

BILLING CODE 4140-01-M

#### National Institute of Health

##### **National Institute of Allergy and Infectious Diseases; Meeting, AIDS Research Advisory Committee, NIAID**

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the AIDS Research Advisory Committee, National Institute of Allergy and Infectious Diseases, on January 30, 1996, in the Executive Board Conference Room D of the Natcher Conference Center, Building 45, at the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland.

The entire meeting will be open to the public from 8 a.m. until adjournment. The AIDS Research Advisory Committee (ARAC) advises and makes recommendations to the Director, National Institute of Allergy and Infectious Diseases, on all aspects of research on HIV and AIDS related to the mission of the Division of AIDS (DAIDS).

The Committee will provide advice on scientific priorities, policy, and program balance at the Division level. The Committee will review the progress and productivity of ongoing efforts, and identify critical gaps/obstacles to progress, and provide concept clearance for proposed research initiatives. Attendance by the public will be limited to space available.

Ms. Anne P. Claysmith, Executive Secretary, AIDS Research Advisory Committee, DAIDS, NIAID, NIH, Solar

Building, Room 2B06, telephone 301-402-0755, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Claysmith in advance of the meeting

(Catalog of Federal Domestic Assistance Program Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Disease Research, National Institutes of Health).

Dated December 14, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 95-30933 Filed 12-19-95; 8:45 am]

BILLING CODE 4140-01-M

#### National Institutes of Health

##### **National Library of Medicine; Notice of Meeting of the Literature Selection Technical Review Committee**

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Literature Selection Technical Review Committee, National Library of Medicine, on February 8-9, 1996, convening at 9 a.m. on February 8 and at 8:30 a.m. on February 9 in the Board Room of the National Library of Medicine, Building 38, 8600 Rockville Pike, Bethesda, Maryland.

The meeting on February 8 will be open to the public from 9 a.m. to approximately 10:30 a.m. for the discussion of administrative reports and program developments. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. Lois Ann Colaianni at 301-496-6921 two weeks before the meeting.

In accordance with provisions set forth in sec. 552b(c)(9)(B), Title 5, U.S.C. Public Law 92-463, the meeting will be closed on February 8, from 10:30 a.m. to approximately 5 p.m. and on February 9 from 8:30 a.m. to adjournment for the review and discussion of individual journals as potential titles to be indexed by the National Library of Medicine. The presence of individuals associated with these publications could hinder fair and open discussion and evaluation of individual journals by the Committee members.

Mrs. Lois Ann Colaianni, Scientific Review Administrator of the Committee, and Associate Director, Library Operations, National Library of Medicine, 8600 Rockville Pike,

Bethesda, Maryland 20894, telephone number: 301-496-6921, will provide a summary of the meeting, rosters of the committee members, and other information pertaining to the meeting.

Dated: December 14, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 95-30932 Filed 12-19-95; 8:45 am]

BILLING CODE 4140-01-M

#### **Notice of the Meeting of the National Advisory Eye Council**

Pursuant to Public Law 92-463, notice is hereby given to the meeting of the National Advisory Eye Council (NAEC) on January 25, 1996, Executive Plaza North, Conference Room G, 6130 Executive Boulevard, Bethesda, Maryland.

The NAEC meeting will be open to the public on January 25 from 8:30 a.m. until approximately 11:30 a.m. Following opening remarks by the Director, NEI, there will be presentations by staff of the Institute and discussions concerning Institute programs and policies. Attendance by the public at the open session will be limited to space available.

In accordance with provisions set forth in Secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and Sec. 10(d) of Public Law 92-463, the meeting of the NAEC will be closed to the public on January 25 from approximately 11:30 a.m. until adjournment at approximately 5:00 p.m. for the review, discussion, and evaluation of individual grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Lois DeNinno, Council Assistant, National Eye Institute, EPS, Suite 350, 6120 Executive Boulevard, MSC-7164, Bethesda, Maryland 20892-7164, (301) 496-9110, will provide a summary of the meeting, roster of committee members, and substantive program information upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. DeNinno in advance of the meeting.